In Paris, France, on May 19, 2026, Ipsen revealed the findings of the Phase IV DIRECTION trial, a comparative study between Dysport (abobotulinumtoxinA) and Botox (onabotulinumtoxinA) for adults with upper limb spasticity (ULS). The results will be disclosed at the International Society of Physical and Rehabilitation Medicine (ISPRM) congress in Vancouver on the same day. The trial demonstrated that Dysport had a comparable safety profile to Botox and provided longer-lasting symptom relief (as per an 80% confidence interval).